Tenet Healthcare (THC) PT Raised to $250 at Raymond James

Raymond James analyst John Ransom raised the price target on Tenet Healthcare (NYSE: THC) to $250.00 (from $200.00) while maintaining a Outperform rating.

The analyst comments "We reiterate our Outperform rating on shares of THC while raising our price target to $250 (~8.5x 2027 EBITDA ex-NCI) following 3Q25 results that exceeded expectations as the company reported adj. EBITDA of $1,099M (Street: $1,035M, RJ: $1,035M), and adj. EBITDA ex-NCI of $862M (RJ: $801M). The quarter did benefit from a $38M out of period DPP, so the core beat was closer to ~$23M all attributable to the hospital division. The quarter, in total, benefited from $346M of supplemental payments."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters